Navigation Links
ARIES System and Flu A/B & RSV Assay Evaluated by Erasmus MC in New Publication
Date:11/17/2016

AUSTIN, Texas, Nov. 17, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the internationally renowned Department of Viroscience at Erasmus Medical Center in Rotterdam, The Netherlands, has evaluated the ARIES® System and Flu A/B & RSV CE-IVD Assay for clinical testing in a recently published study. Erasmus MC is a consultation center for the World Health Organization on viral infections, as well as serving as the National Reference Center for Influenza and Emerging Infections in The Netherlands.

In the study, the ARIES® platform and Flu A/B & RSV Assay showed a high clinical specificity and sensitivity, comparable to laboratory developed RT-PCR assays, and better than those of established assays such as immunochromatographic tests and direct immunofluorescence assays. Ease of use was found to be comparable to other rapid molecular test platforms. The ARIES® platform is unique in that it can also run in-house developed real-time assays with generic ARIES® cassettes.

Continue Reading
The ARIES(R) Flu A/B & RSV Assay is a rapid, accurate method for the detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) from nasopharyngeal swab (NPS) specimens using the ARIES(R) System.
  • The ARIES(R) Flu A/B & RSV Assay is a rapid, accurate method for the detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) from nasopharyngeal swab (NPS) specimens using the ARIES(R) System.

    "We are proud that after thorough evaluation, ARIES has been found to be effective and easy to use by one of the world's leading medical centers for clinical virology," said Thomas Pracht, Managing Director, EMEIA, at Luminex Corporation. "The Erasmus study demonstrates the quality and performance of the ARIES® platform and the value of the system for molecular diagnostic labs that want to perform 'out of sync' MDx testing — in other words, outside of office hours testing or stat testing during office hours in between runs. The study also underlines the importance of 'point of impact' tests, where results have an immediate impact on patient care and clinical decision making, even outside normal office hours." 

    Read the complete study, "Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to-answer assay for the simultaneous detection of Influenza A, B and respiratory syncytial viruses," published in the Journal of Clinical Virology, December 2016, Volume 85, Pages 65–70.

    About Luminex Corporation
    At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity, and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at luminexcorp.com. 

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding the development and testing progress of our pipeline products, and the regulatory approvals thereof. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should", and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    ContactsLuminex Investor ContactLuminex Media ContactHarriss Currie

    Christine ValleSr. Vice President of Finance and CFO

    Sr. Manager, Global Marketing512.219.8020

    512.219.8020hcurrie@luminexcorp.com

    cvalle@luminexcorp.com

    Photo - http://photos.prnewswire.com/prnh/20161116/440243 
    Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO

     

    To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aries-system-and-flu-ab--rsv-assay-evaluated-by-erasmus-mc-in-new-publication-300364612.html


    '/>"/>
    SOURCE Luminex Corporation
    Copyright©2016 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Pennsylvania Department of Health Seeks Public Input on Medical Marijuana Programs Temporary Regulation for Dispensaries/Laboratories
    2. Luminex Corporation to Showcase CE-IVD Marked ARIES System, Revolutionary Software, and Assays at ECCMID Annual Meeting
    3. Kalorama: Use of Primary Research for Device Trends Featured at Pharmaceutical Special Libraries Association Meeting
    4. Medicares Competitive Bidding Program Puts Beneficiaries Lives at Risk
    5. Luminex Corporation Receives Medical Device License for ARIES System and ARIES HSV 1&2 Assay in Canada
    6. Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
    7. Denver Consulting Group Offers Advice for Aspiring Marijuana Cultivators and Dispensaries in Maryland
    8. Pushing the Boundaries of Sight
    9. Luminex Corporation to Feature ARIES System and NxTAG Respiratory Pathogen Panel at AMP Annual Meeting
    10. Natural Partners Now Offers Online Dispensaries to Healthcare Practitioners
    11. New Study Presents Current Service and Cost Benchmarks for Corporate Libraries and Information Centers
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
    (Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
    (Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
    (Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
    (Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
    (Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
    Breaking Medicine News(10 mins):